Literature DB >> 25778100

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.

B Paiva1,2,3, A Azpilikueta2, N Puig4, E M Ocio4, R Sharma5, B O Oyajobi5, S Labiano2, L San-Segundo4, A Rodriguez3, I Aires-Mejia4, I Rodriguez2, F Escalante6, A G de Coca7, A Barez8, J F San Miguel1,2,3, I Melero1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25778100     DOI： 10.1038/leu.2015.79

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

2.  Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.

Authors:  H Tamura; M Ishibashi; T Yamashita; S Tanosaki; N Okuyama; A Kondo; H Hyodo; E Shinya; H Takahashi; H Dong; K Tamada; L Chen; K Dan; K Ogata
Journal:  Leukemia       Date:  2012-07-25       Impact factor: 11.528

3.  A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.

Authors:  B Paiva; M-B Vídriales; L Rosiñol; J Martínez-López; M-V Mateos; E M Ocio; M-Á Montalbán; L Cordón; N C Gutiérrez; L Corchete; A Oriol; M-J Terol; M-A Echeveste; R De Paz; F De Arriba; L Palomera; J de la Rubia; J Díaz-Mediavilla; M Granell; A Gorosquieta; A Alegre; A Orfao; J-J Lahuerta; J Bladé; J F San Miguel
Journal:  Leukemia       Date:  2013-06-07       Impact factor: 11.528

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.

Authors:  William H D Hallett; Weiqing Jing; William R Drobyski; Bryon D Johnson
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-12       Impact factor: 5.742

6.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Authors:  Don M Benson; Courtney E Bakan; Anjali Mishra; Craig C Hofmeister; Yvonne Efebera; Brian Becknell; Robert A Baiocchi; Jianying Zhang; Jianhua Yu; Megan K Smith; Carli N Greenfield; Pierluigi Porcu; Steven M Devine; Rinat Rotem-Yehudar; Gerard Lozanski; John C Byrd; Michael A Caligiuri
Journal:  Blood       Date:  2010-05-11       Impact factor: 22.113

7.  Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.

Authors:  Oihana Murillo; Ainhoa Arina; Sandra Hervas-Stubbs; Anjana Gupta; Brandon McCluskey; Juan Dubrot; Asís Palazón; Arantza Azpilikueta; Maria C Ochoa; Carlos Alfaro; Sarai Solano; José L Pérez-Gracia; Babatunde O Oyajobi; Ignacio Melero
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Authors:  Jacalyn Rosenblatt; Irit Avivi; Baldev Vasir; Lynne Uhl; Nikhil C Munshi; Tami Katz; Bimalangshu R Dey; Poorvi Somaiya; Heidi Mills; Federico Campigotto; Edie Weller; Robin Joyce; James D Levine; Dimitrios Tzachanis; Paul Richardson; Jacob Laubach; Noopur Raje; Vassiliki Boussiotis; Yan Emily Yuan; Lina Bisharat; Viki Held; Jacob Rowe; Kenneth Anderson; Donald Kufe; David Avigan
Journal:  Clin Cancer Res       Date:  2013-05-17       Impact factor: 12.531

9.  Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

Authors:  Ignacio Melero; Antonio M Grimaldi; Jose L Perez-Gracia; Paolo A Ascierto
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
View more
  83 in total

Review 1.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 2.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

3.  Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.

Authors:  Noffar Bar; Federica Costa; Rituparna Das; Alyssa Duffy; Mehmet Samur; Samuel McCachren; Scott N Gettinger; Natalia Neparidze; Terri L Parker; Jithendra Kini Bailur; Katherine Pendleton; Richa Bajpai; Lin Zhang; Mina L Xu; Tara Anderson; Nicola Giuliani; Ajay Nooka; Hearn J Cho; Aparna Raval; Mala Shanmugam; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  JCI Insight       Date:  2020-06-18

Review 4.  Immunopathogenesis and immunotherapy of multiple myeloma.

Authors:  Hideto Tamura
Journal:  Int J Hematol       Date:  2018-01-24       Impact factor: 2.490

Review 5.  Novel Immunotherapies for Multiple Myeloma.

Authors:  Mattia D'Agostino; Mario Boccadoro; Eric L Smith
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

6.  Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.

Authors:  Nicolas Martinez-Calle; Paula Rodriguez-Otero; Sara Villar; Luis Mejías; Ignacio Melero; Felipe Prosper; Patricia Marinello; Bruno Paiva; Miguel Idoate; Jesus San-Miguel
Journal:  Haematologica       Date:  2018-04-12       Impact factor: 9.941

7.  PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Authors:  Natalie A Bezman; Amy Jhatakia; Alper Y Kearney; Ty Brender; Mark Maurer; Karla Henning; Misty R Jenkins; Amy J Rogers; Paul J Neeson; Alan J Korman; Michael D Robbins; Robert F Graziano
Journal:  Blood Adv       Date:  2017-05-08

Review 8.  Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies.

Authors:  Shaji Kumar
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 9.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

Review 10.  Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Authors:  Alexander M Lesokhin; Susan Bal; Ashraf Z Badros
Journal:  Cancer Immunol Res       Date:  2019-08       Impact factor: 11.151
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.